Renalys Pharma
Tokyo
About Renalys Pharma
Renalys Pharma is a clinical-stage biopharmaceutical company based in Japan that focuses on developing treatments for unmet needs in the management of kidney disease for Japanese and Asian patients.2 The company's lead asset is sparsentan, an oral Dual Endothelin Angiotensin Receptor Antagonist (3$\text{DEARA}$), which is licensed for development and commercialization in Asian territories.4
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $38.5M
- Funding stage: M&A
- Last round: Series A (Jul 2024)
- Website: renalys.com
Industries & Categories
Biopharma, Biotechnology, Medical
Canonical: https://fsome.com/organization/renalys-pharma-127088 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.